BeiGene inks $150M deal to follow cancer combo trail blazed by Amgen and Ideaya

BeiGene has struck a $150 million deal to license a cancer candidate from fellow Chinese company CSPC Zhongqi Pharmaceutical Technology, positioning it to explore a drug combination that has attracted the interest of Amgen.